Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06911424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 4 of 38 sitesv10
  2. Study sites: 33 to 38v9
  3. Study sites: 27 to 33
    • Primary completion date: Dec 15, 2025 to Mar 16, 2026
    • Study completion date: Dec 22, 2025 to Mar 23, 2026
    • Secondary endpoints: details revised at 3 of 3 entries
    v8
  4. Site details revised at 1 of 27 sitesv7
  5. Site details revised at 1 of 27 sitesv6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 25 to 27v5
  2. Site details revised at 3 of 25 sitesv4
  3. Site details revised at 3 of 25 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 31, 2025 to Mar 21, 2025
    • Site details revised at 25 of 25 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
Trial Details
NCT Number NCT06911424
Lead Sponsor Baxis Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Bacterial Conjunctivitis
Related terms Bacterial Infections, Conjunctival Diseases, Conjunctivitis, Conjunctivitis, Bacterial, Eye Diseases, Eye Infections, Eye Infections, Bacterial, Infections
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov